求加精: 中国NanoLight公司,怎么样?
The Brightest Light …
NanoLight® Technologies is a division of Prolume Ltd., formed by Prolume’s founder Dr. Bruce Bryan and a group of excellent co-founders from Prolume® Ltd. namely Byron Ballou PhD; Gene Finely MD; Chris Szent-Gyorgyi PhD; Randall Murphy PhD and Miroslav Trampota.
Nanolight® Technology is a biotechnology company developing broad applications of natural, light-emitting marine proteins, or marine bioluminescence. The NanoLight division is focused on becoming the leader in high-value reagent & reporter systems for new product development in the pharmaceutical, agrichemical, and research products industries.
Valuable life science uses for NanoLight®’s technology include high-throughput drug discovery, functional genomics, tumor imaging, replacement of radioisotopes, and molecular diagnostics. One particularly exciting application is the ability to use NanoLight®’s reporter systems to “illuminate” gene and molecular function within living cells, allowing pharmaceutical companies a revolutionary method to study drug activity. A second opportunity is to broadly supply researchers who are increasingly moving away from radioactive reagents toward light-based reporter systems and instruments. NanoLight® Technologies is poised to capitalize on both of these accelerating market trends.
NanoLight’s competitive advantage
Our advantage is based on three crucial proprietary positions:
- Access to the novel bioluminescent and fluorescent protein molecules.
- World’s lowest-cost production technology for coelenterazine (NanoFuel™), necessary for light emission.
-
World’s largest collection of expression libraries from marine bioluminescent organisms.These proprietary technologies, which NanoLight has already developed or protected by patent filings & trade secrets, permit the company to grow into the dominant supplier of proprietary bioluminescent reagents and reporter systems to the life science markets. NanoLight® can immediately provide partners access to:
- Novel GFP genes isolated from Ptilosarcus gurneyi and Renilla Mulleri with distinctive properties including a novel chromophore sequence that differs in 3 of 6 residues from the Aequorea GFP.
- Novel marine luciferases cloned from Renilla Mulleri, Pleuromama sp., and Gaussia sp., the latter appears to be brighter than existing Renilla or Firefly systems in mammalian cells.
- Pending patents on the novel use of bioluminescent proteins on silicon chips for inexpensive high throughput screening and diagnostic applications.
- cDNA libraries from over forty (40) different luminescent organisms for further gene discovery patenting, and licensing.
- Proprietary functional screening methods to identify new bioluminescent genes.
This enormous genetic resource represents an outstanding opportunity for leading life sciences companies racing to establish advanced high-throughput screening and diagnostic systems.
蚂蚁淘主营海外试剂抗体，进口科研仪器，海外试剂耗材等所有行业相关用品进口。蚂蚁淘全球直采，正品保障，为科研献力！如需商业合作，请联系cooperation@ebiomall.com 。
-
重要要推广的品牌Nanocs， chromotek， polysciences， echelon-inc ， Bio-Rad，伯乐 ， R&D Systems， Millipore，密理博 ， Jackson， NEB，New England Biolabs ，Sigma-Aldrich，西格玛奥德里奇， Athens Research & Technology， Illumina ， Tocris ， TwistDx， Enzymatics ，酶科技，Novus，Thermo，thermofisher，赛默飞，赛默飞世尔，gibco、invitrogen，英潍捷基，ambion、ebioscience、molecular probes、ABI，Applied Biosystems、Thermo Scientific，pierce。
全部回答 （共 2 条）
-
Shire采购Berkeley Lights的Beacon“单细胞光导系统”加速细胞株开发 来自 : 蚂蚁淘 发布时间：2018-01-31 爱莫利维尔，美国加州，2018年1月30日——Berkeley Lights,Inc. (BLI)，一家数字化细胞生物学的领导企业，今天宣布Shire公司采购了Beacon“单细胞光导系统”以加速他们的细胞株开发（CLD）进程。Shire的采购决定基于他们对现有的CLD流程和Beacon的CLD流程的对比研究。 基于试运行研究，Beacon系统可以快速高效地鉴定出目标分泌克隆，这样可以节约资源，同时加速开发和发展过程。Berkeley Lights的Beacon系统具有四个模块——输入、培养、检测和输出——可以应用于细胞株开发、抗体开发和工程化、基因编辑和研究等领域。Beacon系统的自动化工作流程利用其精确的个体细胞操控能力，可增加效率并减少整体耗时，同时提供传统技术无法提供的对克隆细胞群的行为的深入洞察。Beacon系统可以在不到一周的时间里筛选数千克隆。 “我们感到非常激动能支持Shire公司，帮助他们增加细胞株开发流程的规模和精确度，并加速创新，”Berkeley Lights公司的CEOEricHobbs博士说，“在Berkeley Lights，我们的使命是提供多样化的平台，整合生物学、技术和信息，使我们的客户能将手动的实验室流程自动化，并聚焦于纯科学（hard science）领域。” 图1.Beacon单细胞光导系统和芯片（放大） 图2.Beacon芯片里的NanoPen 关于BerkeleyLights(BLI) BerkeleyLights,Inc.(BLI)致力于开发能进行生物药、基因组学和细胞治疗应用的一体化平台，并将其商业化。BLI于2016年12月上市了第一个商业化平台：Beacon“单细胞光导系统”*。该平台适用于细胞株开发和直接B细胞（血浆和记忆细胞）抗体开发流程。Beacon平台的灵活性和精确度使用户能进行单细胞分辨率的自动生物过程。BLI也在持续开发新的应用以满足合作者的需求。BLI的技术使客户能够加速学习并动态推进生物药开发流程。
| 图片/货号 | 产品名/品牌 | 价格/货期 | 操作 |
|---|
